Literature DB >> 8310300

Advanced and recurrent endometrial carcinoma: hormonal therapy.

S S Lentz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8310300

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  4 in total

1.  Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors.

Authors:  Anne M Friel; Ling Zhang; Cindy A Pru; Nicole C Clark; Melissa L McCallum; Leen J Blok; Toshi Shioda; John J Peluso; Bo R Rueda; James K Pru
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679

2.  Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.

Authors:  Hakan Karagol; Pinar Saip; Kazim Uygun; Seden Kucucuk; Adnan Aydiner; Erkan Topuz
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 3.  Systemic therapy for advanced or recurrent endometrial carcinoma.

Authors:  G F Fleming
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

4.  Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method.

Authors:  E Smid-Koopman; L J Blok; S Chadha-Ajwani; T J Helmerhorst; A O Brinkmann; F J Huikeshoven
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.